Numerous U.S. states have sued Purdue Pharma for its aggressive marketing and for downplaying OxyContin’s addictiveness. Purdue essentially responded by declaring bankruptcy in 2019. Under the ...

Purdue Pharma and its Sackler family owners have reached a new $7.4 billion settlement to resolve thousands of lawsuits ...

The Sackler family and Purdue Pharma, the maker of the addictive painkiller ... by a monitor and prevents the company from lobbying or marketing opioids. The states involved in the settlement ...

“This epidemic, no doubt, was fueled by Purdue Pharma’s manufacturing and deceptive marketing of OxyContin, a highly potent and addictive drug.” The specific terms require the Sacklers to ...

The prior settlement agreement also was not approved by people affected by Purdue Pharma's marketing of its OxyContin and other opioid-based pain medications, the court ruled. The current ...

Purdue Pharma and the Sackler families agreed Thursday to increase their financial contribution to $7.4 billion to resolve mass opioid litigation.

Purdue Pharma planned to exit bankruptcy last year ... to be overseen by a monitor and will be prevented from lobbying or marketing opioids. "This story is about a family of cruel billionaires ...

Purdue Pharma and its Sackler family owners have ... of the Sackler family of fueling the epidemic through deceptive marketing of its highly addictive pain medicine. Purdue filed for bankruptcy ...

Purdue Pharma and the members of the Sackler family ... to be overseen by a monitor and will be prevented from lobbying or marketing opioids under the settlement. Purdue is the company that ...

NEW YORK, Jan 23 (Reuters) - Purdue Pharma and its Sackler family owners ... Sackler family of fueling the epidemic through deceptive marketing of its highly addictive pain medicine.

NEW YORK — Purdue Pharma and its Sackler family owners have ... the Sackler family of fueling the epidemic through deceptive marketing of its highly addictive pain medicine.